To verify whether MGR was capable of predicting the efficiency of anti-cancer immunotherapies in osteosarcoma patients, we analyzed the expression levels of immunomodulators (HAVCR2, LAG3, CTLA4, PDCD1, GZMA, NKG7, GZMM, IFNG) were significantly increased in low-risk group than high-risk group of TRAGET dataset and GSE21257 dataset. The gene discussed is HAVCR2; the disease is cancer.